Skip to main content
OpenTrials
Completed

NCT Number: NCT02812784

Can Nephrocheck™ Predict the Reversibility of Early, Acute Kidney Injury During Septic Shock?

Patients with septic shock in the intensive care unit have an elevated risk of developing acute kidney injury (AKI).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Amiens, Amiens, France

Loading trial locations.

About this study

Patients with septic shock in the intensive care unit have an elevated risk of developing acute kidney injury (AKI). AKI is an independent factor for mortality. Interventions that limit the worsening of renal function might have an impact on the mortality rate in these patients. Given the absence of validated pharmacological treatments for limiting the progression of AKI or for accelerating recovery from AKI, early intervention and the restoration of the glomerular filtration rate (GFR) in this context of hemodynamic change during the initial phase of septic shock might improve the patients' prognosis. One major challenge is therefore how to determine whether or not the AKI is reversible. The best-studied biomarkers (NGAL and KIM 1) have little discriminant power in septic patients because of their poor specificity or unsuitable kinetics for very early diagnosis. The combination of urine assays for tissue inhibitor of metalloproteinase 2 (TIMP2) and insulin-like growth factor binding protein 7 (IGFBP7) has shown good diagnostic performance for the very early detection of the risk of developing AKI in the following 12 hrs. Urine levels of these two markers specifically reflect damage to kidney tubules. Moreover, the levels appear to be strongly correlated with the severity of tubule damage. Thus, one can reasonably hypothesize that measurement of these markers in the very early stages of septic shock might determine the presence and severity of kidney tubule damage. A threshold (yet to be defined) would help to differentiate between (i) transient, non-severe injury and (ii) injury that is already too severe to be reversible.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 or over
  • Septic shock (according to Bone's criteria) within 4 hours of introduction of catecholamines
  • AKI, characterized by a KDIGO score ≥ 1
  • Social security coverage

Exclusion criteria

  • AKI requiring emergency RRT (in the critical care physician's opinion).
  • Anuria
  • Stage 4-5 chronic kidney failure with a GFR below 30 ml/min.
  • Rapidly progressing renal disorders (glomerulonephritis, HUS, blockage, etc.)
  • Obstructive AKI
  • Probable glomerular damage (nephritic syndrome, nephrotic syndrome, chronic glomerulonephritis)
  • Pregnancy or breastfeeding
  • Legal guardianship or lack of social security coverage.
  • Cardiocirculatory arrest
  • Life expectancy <48 hours.
  • Child C cirrhosis
  • Prior occurrence of AKI during the current hospital stay
  • Transplantation
  • Subject participating in another study with an exclusion period ongoing at the time of the pre-inclusion

Treatment and study plan

Nephrocheck TM

Device

Primary outcomes

  1. KDIGO classification

    Time frame: 72 hours

    predictive value of Nephrocheck™ with regard to the reversibility of AKI, defined as the recovery of normal renal function (KDIGO 0) in the 72 hours following inclusion

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Acronym: AKI-CHECK

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Jun 24, 2016
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.